Skip to main content

Table 1 Clinical and pathological features of patient group

From: Systemic therapy response evaluation in prostate carcinoma with [68Ga]Ga-PSMA-11 PET/CT

Feature   Total
Gleason score 7 7 (26.9%) 26 (100%)
8 9 (34.6%)
9 8 (30.8%)
10 2 (7.7%)
ISUP score 1 0 26 (100%)
2 2 (7.7%)
3 5 (19.2%)
4 9 (34.6%)
5 10 (38.5%)
Risk classification High risk 29 (90.6%) 31 (100%)
Intermediate risk 2 (9.4%)
Low risk 0
Definitive therapy to prostate gland None 41 (87.2%) 47 (100%)
Total prostatectomy 3 (6.4%)
Radiotherapy 3 (6.4%)
Serum PSA value at diagnosis Mean ± standart deviation (minimum–maximum) 510.72 ± 1127.49 (0.22–5476)